Sector News

Lilly announces Joshua Smiley, Anat Ashkenazi appointments

August 10, 2016
Life sciences

Eli Lilly and Company today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October 1. Smiley will replace Thomas Grein, who will retire in September after a 41-year career at Lilly.

Smiley currently serves as senior vice president, Finance, and controller and chief financial officer for Lilly Research Laboratories (LRL). He will report to Derica Rice, executive vice president, Global Services, and chief financial officer.

Succeeding Smiley will be Anat Ashkenazi, vice president, Finance, and chief financial officer for Lilly Manufacturing, Global Quality and Lilly Diabetes.

Grein has been “a steadfast pillar of leadership in our financial organization,” said Rice, explaining that he helped navigate the company in periods of both financial prosperity and uncertainty, including a recent challenging period of patent expirations to a new era of growth.

“With Tom’s guidance, we maintained a strong balance sheet and cash flow that enabled us to make acquisitions and sustain our dividend commitment to Lilly shareholders, even when times were tough,” Rice said.

Having worked with Grein and others to craft and execute aspects of Lilly’s financial strategy, Smiley is extremely well prepared for his new role, Rice said. “Josh’s knowledge and skill helped to place Lilly in a position of strength,” he said. “Josh is a strong analytical and strategic thinker who excels at distilling complex business matters into clear thoughts and actions.”

Smiley has been with Lilly 21 years, serving in a variety of financial, marketing and Six Sigma roles. He has been in his current role since 2011 and before that was vice president, Finance, and chief financial officer for LRL and Lilly Oncology. Smiley is also a member of the board of trustees at Butler University where he serves as treasurer, as well as a member of the board and executive committee for the Indiana Chamber of Commerce.

Ashkenazi joined Lilly 15 years ago. Her career has focused on finance, corporate strategy, business development and Six Sigma. Before assuming her current role she was senior director, Finance, and chief financial officer for Lilly Oncology.

Rice praised Ashkenazi for her strategic thinking, “Anat has a very effective ability to apply strategy into practical solutions. Her exposure to many parts of our organization – including R&D, manufacturing and commercial – combined with her learning agility, energy and commitment, position Anat well for her new role,” he said.

Source: Eli Lilly and Company

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.